Danaher heads into its May 5 earnings call with a notable and quickening contradiction: short sellers have been piling in at a pace not seen this cycle, yet the analyst community is holding its bullish line even as it sharpens pencils on price targets.
The most striking development this week is the speed of short accumulation. Short interest has nearly doubled over the past month, rising 62% to reach 1.25% of the free float. Over the past week alone the position grew another 23%, adding roughly 1.7 million shares. That rate of increase demands attention even if the absolute level remains modest by historical standards. What it tells you is that bears, who were not present in any meaningful way through early April, are making a deliberate pre-earnings bet against the stock. The move from roughly 4.4 million shorted shares in early April to 8.8 million now has been nearly uninterrupted.
The lending market, however, suggests this is not a crowded trade. Availability is loose — utilization barely registers at 0.17% against a 52-week peak of 1.4% — and cost to borrow is just 0.41%, well within the range it has occupied for months. Bears are paying nothing for the privilege. There is no squeeze pressure building and no evidence that the borrow pool is being strained. The options market tells a different story. The put/call ratio hit 1.02 on Tuesday, nearly two standard deviations above its 20-day mean of 0.79, its most defensive reading in weeks. That aligns with the short-building: investors are either hedging into the print or expressing outright downside views through both channels simultaneously. The PCR has not been this elevated since March.
The Street is reluctant to abandon the bull case even so. Every analyst move this week maintained the existing rating. Morgan Stanley held Overweight but cut its target from $270 to $255. Goldman Sachs holds Buy with a trimmed target of $230, down from $265. UBS, Guggenheim, and Baird all brought numbers down in the $235–$250 range while keeping positive ratings. The message is uniform: fundamentals are intact, but the macro and China headwinds are real and the valuation buffer has narrowed. The consensus sits at buy with 19 buy ratings and 3 outperform. No single analyst has moved to the sidelines. With the stock at $178.80, even the most cautious target — Wells Fargo's equal-weight at $212 — implies more than 18% upside, and the cluster of bull-case targets sits around $240–$255.
Valuations have compressed through April. The P/E has come down roughly 0.74 turns over the past 30 days to just under 20.7x, and EV/EBITDA has drifted lower by 0.17x over the same period to 16.9x. Those moves are modest, but they reflect the market's reluctance to re-rate higher with China risk unresolved. The factor-score picture is mixed. A 99th-percentile ranking on forward EPS year-on-year growth is a standout — the Street's earnings revision trajectory remains firmly positive. EPS momentum over 30 days clocks in at the 62nd percentile. Short score rank at 84th percentile is climbing but the raw ORTEX short score of 29.5 remains far from extreme territory.
The most recent earnings print is a relevant data point. When DHR reported on April 21, the stock fell 5.9% on the day and 8.5% over the following week. That context sits behind the positioning right now. Peers have had a rough week too: TMO dropped 10.4% over the last five sessions, RVTY fell 9.6%, and TECH lost 10.3%. Danaher's 2.8% weekly decline is meaningfully better than that peer group, which suggests either relative resilience in the name or that the incremental short pressure is stock-specific rather than sector-wide.
The May 5 earnings call is the obvious next event. The key tension is not whether near-term numbers disappoint — that risk is already being hedged — but whether management's commentary on the China recovery timeline and the bioprocessing end-market gives the Street any reason to stop trimming targets.
See the live data behind this article on ORTEX.
Open DHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
